NOVEL 2 – AMINO – N’ – (2-OXOINDOLIN – 3 – YLIDENE) BENZO [d] OXAZOL – 5 -CARBOHYDRAZIDES AS ANTI-INFLAMMATORY AGENTS
HTML Full TextNOVEL 2 – AMINO - N' - (2-OXOINDOLIN – 3 - YLIDENE) BENZO [d] OXAZOL – 5 -CARBOHYDRAZIDES AS ANTI-INFLAMMATORY AGENTS
A. Lavanya *, Arunadevi Parlapalli, Manasa Ciddi andSarangapani M
University College of Pharmaceutical Sciences, Kakatiya University, Warangal, India
ABSTRACT:
In the present work , novel 2-Amino-N'-(2-oxoindolin-3-ylidene) benzo[d]oxazole-5-carbohydrazides were synthesized and evaluated for In-vivo anti-inflammatory activity by carragenan induced rat paw edema method and were known to exhibit promising anti-inflammatory activity at a dose of 30mg/kg bw. Compounds D2, D3, D5 and D8 were found to be comparatively potent with the standard Indomethacin.
Keywords: |
Benzoxazole; Antiinflammatory; prostaglandin; Isatins; Indomethacin, carrageen
INTRODUCTION: Relief of pain and inflammation is human being is a major challenge for medicinal chemistry researchers. Non-steroidal anti-inflammatory agents currently in use are characterized by their ability to relieve the pain of both pathological and non-pathological inflammation associated with inflammatory disorders and to inhibit the synthesis of endogenous prostaglandins (PGs) which are the mediating factors for the inflammation process. They competitively inhibit cyclooxygenases (COXs) and elicit their therapeutic effects by inhibition of prostaglandin (PG) synthesis. Specifically by the enzymes that catalyze the synthesis of cyclic endoperoxides from arachidonic acid to form prostaglandins. Two COX isoenzymes have been identified: COX-1 and COX-2.
COX-1, expressed constitutively, is synthesized continuously and is present in all tissues and cell types, most notably in platelets, endothelial cells, the GI tract, renal microvasculature, glomerulus, and collecting ducts. COX-2 is considered an inducible isoenzyme, although there is some constitutive expression in the kidney, brain, bone, female reproductive system, neoplasias, and GI tract. The COX-2 isoenzyme plays an important role in pain and inflammatory processes 1.
Among the heterocycles, Benzoxazoles occupy a unique place in the realm of natural and synthetic organic chemistry and it is considered as structural isosteres ofthe naturally occurring nucleic bases adenine and guanine, which allow them to interact easilywith polymers of living systems and possess most remarkable and a wide range of biological activities. The substituted benzoxazoles have been shown to exhibit antitumor, antihistaminic, antiparasitic, and herbicidal, anti allergic, antihelmintic, COX-2inhibitory, antifungal, antibacterial, anticancer, antitubercular, anticonvulsant, diarrhoea-predominant irritable bowel syndrome, hypoglycaemic, HIV-1 reverse transcriptase inhibitor & insecticidal activities 2-16. It has also been shown to have binding affinity to Aβ42 fibrils. On the other hand, Isatins are an important group of heterocyclic compounds which are biologically active and of significant importance in medicinal chemistry.
A variety of biological activities are associated such as analgesic, anticonvulsant, antidepressant, anti-inflammatory, antimicrobial activity and effects on the central nervous system identified in animals as a major component of the endogenous monoamine oxidase inhibitor 17-34. In this communication we described the synthesis of hybrid molecules consisting of Benzoxazoles along with Isatin moiety highlighted their in -vitro anti-inflammatory activity.
Experimental:
Chemistry:
All chemicals used in this study were purchased from E. Merck, Aldrich companies. Melting points were recorded on VMP-AM melting point apparatus. Proton Nuclear Magnetic Resonance spectra were recorded on Varian Gemini 200, Avance 300 and Varian Unity 400 spectrometers using tetramethylsilane (TMS) as an internal standard and chemical shifts are shown in δ scale. Infrared spectra were recorded on Perkin-Elmer 1310 infrared spectrometer.
Electron Impact (EI) and Chemical ionization mass spectra (CIMS) were recorded on VG 7070 H ev instrument at 70 ev. Silica gel used for column chromatography was purchased from ACME chemical company. All reactions were monitored by thin layer chromatography (TLC) on precoated silica gel 60 F254 (Merck); spots were visualized with UV light.
Synthesis of Indole-2, 3-diones (isatins):
Isonitrosoacetanilides: In a 5 L R.B. Flask were placed 90g (0.54mol) of chloral hydrate and 1200 ml of water. To this solution, were then added crystallized sodium sulphate (1300 g) followed by a solution of appropriate aniline (0.5mol) in 300 ml of water, to which 51.2g (43ml, 0.52 mol) of concentrated Hydrochloric acid has been added to dissolve the aniline. Finally, a solution of hydroxylamine HCl, 110g (1.58mol) in 500 ml of water was added. The contents of the flask were heated on water bath so that vigorous boiling began in about 40 to 45 minutes. After 1 to 2 minutes of vigorous boiling the reaction was completed. During the heating period, some crystals of isonitrosoacetanilide separated out. On cooling the solution in running water, the remaining crystallized. It was filtered under suction and air dried.
Indole-2, 3-diones – Sulphuric acid (600 g, 326 ml, sp.gr. 1.84) was warmed at 500C in a 1 litre R.B. flask fitted with an efficient mechanical stirrer, and to this, 0.46mol of dry finely powdered appropriate isonitrosoacetanilide was added at such a rate so as to maintain the temperature between 60°C to 70°C but not higher. External cooling was applied at this stage so that the reaction could be carried out more rapidly.
After the addition of isonitrosoacetanilide was completed, the solution was heated to 80°C and maintained at that temperature for 10 minutes to complete the reaction. Then the reaction mixture was cooled to room temperature and poured up on 10 to12 times the volume of crushed ice while stirring. After standing for about half-an-hour, the product separated was filtered, washed several times with small portions of cold water, several times to remove sulphuric acid. It was then air dried.
Synthesis of Methyl 4-hydroxy-3-nitrobenzoate (2): To a solution of aluminium nitrate (40 g) in glacial acetic acid: acetic anhydride (1:1, v/v) mixture (160 ml) 40 g of Methyl-4-hydroxybenzoate (1) was added in small portions, while heating gently; cooling and shaking occasionally. The reaction mixture was left at room temperature for 1.5 h while shaking the contents intermittently to complete the nitration. The resulting brown solution was diluted with ice cold water (500 ml) to get a bulky yellow precipitate of methyl 4-hydroxy-3-nitrobenzoate.(mp= 73°C)
Synthesis of Methyl 3-amino-4-hydroxybenzoate (3):Methyl 4-hydroxy-3-nitrobenzoate (2, 40 g) was dissolved in boiling ethanol (400 ml) and sodium dithionite was added to this boiling alcohol solution until it becomes almost colourless. Then the solvent was reduced to one third of its volume by distillation and to the residual liquid, ice cold water was added. The resulting shiny product (3) was filtered, washed with cold water and dried. (mp= 143ºC)
Synthesis of Methyl 2-aminobenzo[d]oxazol-5-carboxylate (4): 1.3 moles of methyl 3-Amino-4-hydroxybenzoate (3) was dissolved in 1L Methyl alcohol and cooled the solution to 5ºC by adding chopped ice. A cold suspension of 1.5 moles of Cyanogen bromide in 1L of water was added over a period of 5min with rapid stirring. Continuing the stirring for 0.75h at room temperature, 1.3moles of solid Sodium bicarbonate in small portions over a period of 1.5 h was added to bring the pH 6.5 -7.0. Stirring was continued for another 1h. The solid was separated by filtration, washed with cold water and on recrystallization from ethyl alcohol has resulted white solid. (mp= 243°C)
Synthesis of 2-Aminobenzo[d]oxazol-5-carbohydrazide (5): A mixture of Methyl-2-aminobenzoxazole-5-carboxylate (4, 0.01mol) and hydrazine hydrate (99%) (0.01mol) were taken in 50ml of alcohol, heated under reflux on a water bath for 5hrs. The alcohol was reduced to half of its volume and cooled. The product separated was filtered and washed with small portions of cold alcohol first and then with cold water repeatedly and dried. The product purified by recrystallization from methanol has resulted white solid.
FIGURE: 1 Synthesis of 2--Amino-N'-(2-oxoindolin-3-ylidene) benzo [d] oxazol-5-carbohydrazide (7)
Synthesis of 2-Amino-N'-(2-oxoindolin-3-ylidene) benzo[d]oxazol-5-carbohydrazide (7):
The 2-aminobenzo[d]oxazole-5-carbohydrazide (5, 0.01mol) and appropriate isatin (6, 0.01mol) in methanol (20ml), 2 drops of glacial acetic acid heated under reflux on a water bath for 8 to 12 h. The product thus obtained was filtered, washed with water and air dried.
Pharmacological evaluation:
Plethysmograph, Carrageenan, Indomethacin, Test compounds, Normal saline, water, 1ml reusable glass syringe, needles for intraperitonial injection, marker pens, cotton, 0.1% Sodium CMC suspension.
Animals:
All the experiments were carried out using male, Sprague-Dawley rats (300-350 g) were obtained from animal house, UCPSc, Kakatiya University, Warangal, India. On arrival the animals were placed at random and allocated to treatment groups in polypropylene cages with paddy husk as bedding. Animals were housed at a temperature of 24 ± 2oC and relative humidity of 30 – 70 %. A 12:12 light: day cycle was followed. All animals were allowed to free access to water and fed with standard commercial rat chew pellets. All the experimental procedures and protocols used in this study were reviewed by the Institutional Animal Ethics Committee, Kakatiya University, Warangal, India.
Preparation of carrageenan suspension:
1% w/v suspension of carrageenan was prepared by adding 100mg of carrageenan powder to 10ml of saline (0.9% NaCl) solution and set aside to soak for 1 hour. A homogenous suspension was then obtained by thorough mixing with a magnetic stirrer.
Experimental Procedure:
Sprague-Dawley strain Albino rats of either sex, weighing between 250-300 g, fasted overnight before the test and allowed water ad libitum, were divided into ten groups of six animals each. The volume of the right hind paw was measured using a plethismograph. This constituted the initial reading. The test compounds were tested at a dose of 30mg/kg body weight. Indomethacin 5mg (0.014mmoles)/kg body weight was used as standard. All these were administered as suspensions using sodium CMC (0.1% w/v) as suspending agent.
Control group of animals received a suspension of sodium CMC only. All these were administered intraperitonially 1h before the injection of carrageenan. 0.1 ml of 1% w/v carrageenan suspension in normal saline was injected in to the plantar region of the right hind paw.
The swelling produced after injection of the carrageenan was measured at 2hour intervals for 8 hours. Percentage inhibition of edema was calculated using the formula given below:
RESULTS AND DISCUSSION:
Synthesis:
Methyl4-hydroxy benzoate upon nitration with aluminium nitrate in presence of glacial acetic acid and acetic anhydride produces methyl-4-hydroxy-3-nitrobenzoate and undergoes reduction in presence of sodium dithionate to form methyl 3-amino-4-hydroxy benzoate (3) which undergoes cyclization in presence of cyanogenbromide to form methyl – 2 - amino- benzo [d] oxazol – 5 -carboxylate (4) upon treatment with hydrazine hydrate produces 2-Aminobenzo [d] oxazol – 5 -carbohydrazide upon reaction with substituted Isatins (6) yields 2 – Amino - N' - (2-oxoindolin-3-ylidene) benzo [d] oxazol – 5 - carbohydrazide (7) Yields and Melting point of the intermediates (Table 2) and 2-Amino-N'-(2-Oxoindolin-3-Ylidene) Benzo [D]Oxazol - 5 Carbohydrazides (Table 1). The structures of the compounds were confirmed by spectral studies such as IR, 1H NMR and MS 35-37.
Acute toxicity 38:
All the compounds are evaluated for acute toxicity and well tolerated by the experimental animals and it has been found to be non-toxic and safe even up to a dose of 300mg/kg bodyweight orally.
Anti-inflammatory activity 39:
All the synthesized compounds (D1-D6) were subjected for in-vivo anti-inflammatory activity by carragenean induced rat paw odema method at a dose of 30 mg/kg body weight using Indomethacin as a reference standard. 2-Amino-N'-(2-oxoindolin-3-ylidene) benzo [d] oxazole – 5 - carbohydrazides showed promising anti-inflammatory activity The Percentage Inhibition was determined (Table 4).
Among the synthesized compounds D2 (R= 5-chloro), D3 (R= 7-chloro), D5 (R= 5-methyl) and D8 (R= 5-fluoro, 6-chloro) were found to be comparatively potent with 36.76 (6h), 31.77(8h), 31.37(6h), 32.60(6h) percentage inhibition of paw edema respectively and the compounds D4 (R= 6-methyl) and D6(5, 7-dibromo) showed weak anti-inflammatory activity with 15.76 (4h), 7.84 (6h) percentage inhibition of paw edema respectively and are shown in Table 3 and Figure 2.
TABLE 1: PHYSICAL DATA OF 2-AMINO-N'-(2-OXOINDOLIN - 3 - YLIDENE) BENZO [d] OXAZOL - 5 -CARBOHYDRAZIDES:
Compound | R | Molecular formula | Molecular weight | Melting point (°C) | Percentage yield |
D1 | H | C16H11N5O3 | 321.9 | 315 | 73 |
D2 | 5-Cl | C16H10ClN5O3 | 355.74 | 320 | 75 |
D3 | 7-Cl | C16H10ClN5O3 | 355.74 | 310 | 70 |
D4 | 6-CH3 | C17H13N5O3 | 335.32 | 325 | 76 |
D5 | 5-CH3 | C17H13N5O3 | 335.32 | 305 | 82 |
D6 | 5,7-diBr | C16H9Br2N5O3 | 479.08 | 310 | 75 |
D7 | 5-Br | C16H10BrN5O3 | 399.18 | 330 | 77 |
D8 | 5-F, 6-Cl | C16H9FClN5O3 | 373.73 | 350 | 76 |
TABLE 2: PHYSICAL DATA OF INDOLE 2, 3 DIONES
S.no. | Compound | R | Molecular formula | Molecular weight | Melting point (°C) | Percentage yield |
1 | I1 | H | C8H5NO2 | 147.10 | 200 | 70 |
2 | I2 | 5-Cl | C8H4ClNO2 | 181.58 | 255 | 65 |
3 | I3 | 7-Cl | C8H4ClNO2 | 181.58 | 190 | 68 |
4 | I4 | 6-CH3 | C9H7NO2 | 161.16 | 170 | 72 |
5 | I5 | 5-CH3 | C9H7NO2 | 161.16 | 184 | 75 |
6 | I6 | 5,7-diBr | C8H3Br2NO2 | 305.00 | 250 | - |
7 | I7 | 5-Br | C8H4BrNO2 | 225.03 | 248 | - |
8 | I8 | 5-F, 6-Cl | C8H3FClNO2 | 199.57 | 240 | 62 |
TABLE 3: SHOWING THE MEAN PAW EDEMA VOLUME (n=6) OF 2-AMINO-N'-(2-OXOINDOLIN-3-YLIDENE) BENZO[d] OXAZOL-5-CARBOHYDRAZIDES (30mg/kg bw) COMPARED TO STANDARD DRUG INDOMETHACIN (5mg/kg bw)
Compound | R | Mean paw edema Volume(ml) ± SD | ||||
0h | 2h | 4h | 6h | 8h | ||
D1 | H | 0.400±0.00 | 0.720±0.075 | 0.650±0.055 | 0.616±0.041 | 0.533±0.052 |
D2 | 5-Cl | 0.434±0.052 | 0.650±0.075 | 0.566±0.086 | 0.516±0.041 | 0.500±0.000 |
D3 | 7-Cl | 0.399±0.075 | 0.650±0.058 | 0.667±0.052 | 0.600±0.063 | 0.466±0.052 |
D4 | 6-CH3 | 0.417±0.04 | 0.700±0.00 | 0.716±0.041 | 0.766±0.041 | 0.600±0.00 |
D5 | 5-CH3 | 0.417±0.04 | 0.566±0.057 | 0.65±0.05 | 0.560±0.045 | 0.530±0.051 |
D6 | 5,7-diBr | 0.434±0.08 | 0.75±0.055 | 0.816±0.075 | 0.75±0.084 | 0.63±0.052 |
D7 | 5-Br | 0.450±0.054 | 0.583±0.026 | 0.78±0.04 | 0.65±0.082 | 0.60±0.040 |
D8 | 5-F, 6-Cl | 0.483±0.09 | 0.60±0.054 | 0.60±0.119 | 0.55±0.093 | 0.50±0.098 |
Indomethacin | 0.416±0.04 | 0.596±0.083 | 0.526±0.134 | 0.480±0.092 | 0.447±0.080 | |
Control | 0.434±0.05 | 0.780±0.098 | 0.850±0.055 | 0.816±0.075 | 0.683±0.041 |
Spectral data:
2 – Amino - N' - (2-oxoindolin – 3 - ylidene) benzo [d] oxazol – 5 - carbohydrazide (D1)
IR (KBr, cm-1): 3392.12, 3167.50 (NH2 str.), 1685.77(C=O str.), 1139.28 (C-O str.);
1H NMR (DMSO-d6, 400 MHz) δ = 13.85 (s, 1H, NH), 11.38 (s, 1H, NH), 7.75(s, 2H, NH2), 7.68-7.54 (m, 4H, Ar-H), 7.43-7.38(t, 1H, Ar-H), 7.14-7.10(t, 1H, Ar-H), 6.98(s, 1H, Ar-H) ppm; Mass spectrum (ESI): (M+) 321.9 m/z ;HRMS: 321.90
2 – Amino -N'- (5-chloro-2-oxoindolin-3-ylidene) benzo[d]oxazol-5-carbohydrazide (D2):
IR (KBr, cm-1): 3392.12, 3167.50 (NH2 str.), 1685.77(C=O str.), 1139.28 (C-O str.)
1H NMR (DMSO-d6, 400 MHz) δ = 13.85 (s, 1H, NH), 11.38 (s, 1H, NH), 7.75(s, 2H, NH2), 7.68-7.54 (m, 2H, Ar-H), 7.46-7.50(s,1H,Ar-H),7.43-7.38(t, 1H, Ar-H), 7.14-7.10(t, 1H, Ar-H), 6.98(s, 1H, Ar-H) ppm; Mass spectrum (ESI): 355; HRMS:355.15
2 – Amino - N' - (7-Chloro – 2 – oxoindolin – 3 -ylidene) benzo[d]oxazol- 5-carbohydrazide (D3):
IR (KBr, cm-1): 3392.12, 3167.50 (NH2 str.), 1685.77(C=O str.), 1139.28 (C-O str.)
1H NMR (DMSO-d6, 400 MHz) δ = 13.85 (s, 1H, NH), 11.38 (s, 1H, NH), 7.75(s, 2H, NH2), 7.68-7.54 (m, 3H, Ar-H), 7.43-7.38(t, 1H, Ar-H), 7.14-7.10(t, 1H, Ar-H), 6.98(s, 1H, Ar-H) ppm;Mass spectrum (ESI): 355; HRMS: 355.10
2 – Amino - N'- (6-methyl-2-oxoindolin - 3-ylidene) benzo[d] oxazol-5-carbohydrazide (D4):
IR (KBr, cm-1): 3392.12, 3167.50 (NH2 str.), 1685.77(C=O str.), 1139.28 (C-O str.)
1H NMR (DMSO-d6, 400 MHz) δ = 13.85 (s, 1H, NH), 11.38 (s, 1H, NH), 7.75(s, 2H, NH2), 7.68-7.54 (m, 2H, Ar-H), 7.43-7.38(t, 1H, Ar-H),7.23-7.32(s,1H,Ar-H) 7.14-7.10(t, 1H, Ar-H), 6.98(s, 1H, Ar-H),2.0 (s,3H,CH3) ppm.; Mass spectrum (ESI):335;HRMS: 335.12
2-Amino-N'- (5 – methyl - 2-oxoindolin – 3 -ylidene) benzo[d] oxazol-5-carbohydrazide (D5):
IR (KBr, cm-1): 3392.12, 3167.50 (NH2 str.), 1685.77(C=O str.), 1139.28 (C-O str.)
1H NMR (DMSO-d6, 400 MHz) δ = 13.85 (s, 1H, NH), 11.38 (s, 1H, NH), 7.75(s, 2H, NH2), 7.68-7.54 (m, 2H, Ar-H), 7.43-7.38(t, 1H, Ar-H),7.23-7.32(s,1H,Ar-H) 7.14-7.10(t, 1H, Ar-H), 6.98(s, 1H, Ar-H),2.0 (s,3H,CH3) ppm.
Mass spectrum (ESI): 335
2 - Amino - N'- (5, 7- dibromo - (2-oxoindolin -3-ylidene) benzo [d] oxazol – 5 - carbohydrazide (D6): IR (KBr, cm-1): 3404.46, 3247.59 (NH2 str.), 1690.05 (C=O str.), 1141.28 (C-O-C str.)
1HNMR (DMSO-d6, 400 MHz): δ = 13.8 (s, 1H, NH), 11.25 (s, 1H, NH), 7.87 (s, 1H, Ar-H), 7.8 (s, 1H, Ar-H), 7.74 (s, 1H, Ar-H), 7.65 (s, 2H, NH2), 7.56(d, 1H, Ar-H), and 7.52 (d, 1H, Ar-H) ppm.; Mass spectrum: ESI- 479.7; HRMS: 479.9
2 – Amino - N'- (5-bromo-2-oxoindolin-3-ylidene) benzo[d]oxazol-5-carbohydrazide (D7):
IR (KBr, cm-1): 3392.12, 3167.50 (NH2 str.), 1685.77(C=O str.), 1139.28 (C-O str.)
1H NMR (DMSO-d6, 400 MHz) δ = 13.85 (s, 1H, NH), 11.38 (s, 1H, NH), 7.75(s, 2H, NH2), 7.68-7.54 (m, 2H, Ar-H), 7.46-7.50(s,1H,Ar-H),7.43-7.38(t, 1H, Ar-H), 7.14-7.10(t, 1H, Ar-H), 6.98(s, 1H, Ar-H) ppm.Mass spectrum:ESI-400;HRMS: 400.09
2-Amino- N - 5 Fluoro-7-dibromo-2-oxoindolin-3-ylidene) benzo [d] oxazol - 5 - carbohydrazide (D8): IR (KBr, cm-1): 3404.46, 3247.59 (NH2 str.), 1690.05 (C=O str.), 1141.28 (C-O-C str.) ;1H NMR (DMSO-d6, 400 MHz): δ = 13.8 (s, 1H, NH), 11.25 (s, 1H, NH), 7.87 (s, 1H, Ar-H), 7.8 (s, 1H, Ar-H), 7.74 (s, 1H, Ar-H), 7.65 (s, 2H, NH2), 7.56(d, 1H, Ar-H), and 7.52 (d, 1H, Ar-H) ppm. Mass spectrum: ESI-373; HRMS: 373.73
FIGURE2: GRAPHICAL REPRESENTATION OF PERCENTAGE INHIBITION OF PAW ODEMA METHOD
CONCLUSIONS:2 – Amino - N' - (2-oxoindolin-3-ylidene) benzo [d] oxazole – 5 - carbohydrazides showed promising anti-inflammatory activity. At a dose of 30mg/kg bw, compounds D2 (R= 5-chloro), D3 (R= 7-choro), D5 (R= 5-methyl) and D8 (R= 5-fluoro, 6-chloro) were found to be comparatively potent with 36.76 (6h), 31.77(8h), 31.37(6h), 32.60(6h) percentage inhibition of paw edema respectively and the compounds D4 (R= 6-methyl) and D6(5, 7-dibromo) showed weak anti-inflammatory activity with 15.76 (4h), 7.84 (6h) percentage inhibition of paw edema respectively.
ACKNOWLEDGEMENTS: Author thanks UCPSc, Kakatiya university, Warangal.
REFERENCES:
- Jack DeRuiter Non-Steroidal Antiinflammatory Drugs (NSAIDS). Principles of Drug Action 2002; 2: 1-26.
- Gong B; Hong F; Kohm C; Bonham L and Klein P Bioorganic and Medicinal Chemistry 2006; 14:1455.
- Russell D. Viirre; Ghotas Evindar; Robert A; Batey Journal of Organic Chemistry 2008;73:3452.
- Reiser A; Leyshon L J; Saunders D; Mijovic M. V; Bright A ; Bogie J Journal of American Chemical Society, 1972;2414.
- www.aurolabs.com/pdf/api/new/CHLORZOXAZONE.pdf.
- Borje Kuillaback and Auti Ilaruanne, Zoxazolamine as Uricosuric agent. Acta Medica Acandinavica 1961; 170:129-132.
- Ramanatham Vinod Kumar Synthetic Strategies towards Benzoxazole Ring Systems: A Review. Asian Journal of Chemistry 2004; 16, 4: 1241-1260.
- Schnürch, J; Hämmerle and P. Stanetty Product Class 13: Benzoxazoles and Other Annulated O xazoles. Science of Synthesis Updates 2010; 11:1-56.
- Srinivas Ampati; Raju Jukanti; Vidya Sagar; Rama Ganta ; Sarangapani Manda Synthesis and in vivo anti-inflammatory activity of a novel series of benzoxazole derivatives.Pelagia Research Library 2010; 1 (3): 157-168.
- H. Ozan G; Serdar ¨UNL¨U; Erden BANOGLU; M. Fethi SAHIN Synthesis of New 4-(5-Chloro-2-oxo-3H-benzoxazol-3-yl) butanamide Derivatives and their Analgesic and Anti-Inflammatory Properties. Turk J Chem 2003; 27:467-476.
- Ilkay O¨ ren; O¨ zlem Temiz; Ismail Yalcın; Esin Sener and Nurten Altanlar Synthesis and antimicrobial activity of some novel 2,5- and/or 6-substituted benzoxazole and benzimidazole derivatives. European Journal of Pharmaceutical Sciences 1998; 7: 153–160.
- Aysegul Akbay; IIkay Oren; Ozlem Temiz-Arpaci and Ismail Yalcin HIV-1 Reverse Transcriptase Inhibitors. Arzneim Forsch Drug Res. 2003; 4:267-271.
- Emine Oksuzoglu; Betul Tekiner-Gulbas; Sabiha Alper Ozlem; Ilkay Yildiz and Nuran Diril Some Benzoxazoles and Benzimidazoles as DNA Topoisomerase I and II Inhibitors.Journal of Enzyme Inhibition and Medicinal Chemistry2008; 23: 37–42.
- Pu Xiang; Tian Zhou ; Liang Wang; Chang-Yan Sun; Jing Hu; Ying-Lan Zhao and Li Yang Synthesis and Preliminary in Vitro Biological Evaluation of Novel Benzothiazole, Benzimidazole andBenzoxazoleDerivatives as Potential Antitumor Agents. Molecules 2012; 17: 873-883.
- Nadeem Siddiqui; M. Sarafroz; M. Mumtaz Alam and Waquar Ahsan Synthesis, Anticonvulsant and Neurotoxicity Evaluation of 5-Carbomethoxybenzoxazole Derivatives. Acta Poloniae Pharmaceutica-Drug Research, 2008; 65, 4:449-455.
- Nageshwar Rao Chilumuru; Srinivas Ampati; Sarangapani Manda; Dayakar Gadhe (2011) Synthesis and in vivo evaluation of anti-inflammatory activity of 5-(2-(2-(arylideneamino) oxazol-5-ylamino) benzoxazol-5-yl)-3-((dialkylamino) methyl)-1, 3, 4-oxadiazole-2(3H)-thiones. Journal of Advanced Pharmaceutical Sciences, 2011; 1:16-21.
- Joaquim F. M. da Silva; Simon J. Garden; Angelo C. Pinto The Chemistry of Isatins: a Review from 1975 to 1999. J. Braz. Chem. Soc., 2001;12: 273-324.
- CH Suresh; J. Venkateshwara Rao; KN Jayaveera Anti Inflammatory Activity of 3-(2-Hydrazino Benzothiazoles) -Substituted Indole-2-One. International Journal of Pharmacy and Pharmaceutical Science Research 2011; 1(1):30-34.
- Venkateshwarlu E; Venkateshwar Rao J; Umasankar K ; Dheeraj G Study of Anti-Inflammatory, Analgesic and Antipyretic activity of Novel Isatin Derivatives. Asian Journal of Pharmaceuitical and Clinical Research 2012; 5(4):187-190.
- Nilanjan Pahari; Dibyajyoti Saha; Vibhor K; Jain, Bindu Jain ; Debajyoti Mridha Synthesis and Evaluation of Acute Toxicity Studies and Analgesic Characters of some Novel Indole Derivatives. International Journal of Pharmaceutical Sciences and Research, 2010; 1(9): 399-408.
- U. K. Singh; S. N. Pandeya; A. Singh; B. K. Srivastava ; M. Pandey Synthesis and Antimicrobial Activity of Schiff’s and N-Mannich Bases of Isatin and its Derivatives with 4-Amino-N-Carbamimidoyl Benzene Sulfonamide.International Journal of Pharmaceutical Sciences and Drug Research 2010; 2(2): 151-154.
- Nalan Terzioglu; Nilgün Karal; Aysel Gürsoy; Christophe Pannecouque (2006) Synthesis and primary antiviral activity evaluation of 3-hydrazono-5-nitro-2-indolinone derivatives. ARKIVOC 2006; 109-118.
- Tarek Aboul-Fadl; Faragany Abdel-Hamid; Mohammed; Ehsan Abdel-Saboor Hassan Synthesis, Antitubercular Activity and Pharmacokinetic Studies of some Schiff Bases Derived from 1- Alkylisatin and Isonicotinic Acid Hydrazide (INH). Archives of Pharmacal Research, 2003; 26(10): 778-784.
- Chinnasamy Rajaram Prakash; Sundararajan Raja Govindaraj Saravanan Synthesis, Characterization and Anticonvulsant Activity of Novel Schiff Base of Isatin Derivatives. International Journal of Pharmacy and Pharmaceutical Sciences 2010, 2(4), pp 177-181.
- Sivakumar Smitha, Surendra N. Pandeya, James P. Stables and Suthakar Ganapathy (2008) Anticonvulsant and Sedative-Hypnotic Activities of N-Acetyl / Methyl Isatin Derivatives.Scientia Pharmaceutica. 2008,76, 621-636
- C.R. Prakash; S. Raja; G. Saravanan; P. Dinesh Kumar; T. Panneer Selvam Synthesis and Evaluation of Antioxidant Activities of Some Novel Isatin Derivatives and Analogs. Asian J. Res. Pharm. Sci. 2011; 1(4): 140-143.
- Sondhi SM; Singh N; Kumar A; Lozach O; Meijer L Bioorg. Med. Chem 2006; 14:3758.
- Vinsova J; Cermakova K; Tomeckova A; Ceckova M; Jampilek J; Cermak P; Kunes J; Dolezal M; Staud F Bioorganic and Medicinal Chemistry 2006;14: 5850.
- http://ci.nii.ac.jp/vol_issue/nels/AN00154136/ISS0000422025_en.html.
- http://aac.asm.org/content/55/3/974.full
- David A. WILLIAMS; Victoria F. ROCHE; S. William ZITO Nonsteroidal Anti-Inflammatory Drugs, FOYE’S principles of medicinal chemistry 2008;6: 969-970. Lippincott Williams & Thomas L. LEMKE;
- C. S. Marvel; G. S. Hiers.Organic Syntheses, Coll. (1941) 1, 327.
- H.G. Lindwall; J. Bandes; L. Weinberg Journal of American Chemical Society 1931;53: 317
- O. P. Agarwal,Heterocyclic compounds, Benzo-condensed pyrroles, furans and thiophene, Indole. Reactions and Reagents, 2006; 42:658, Goel publication house.
- Donald L Pavia; Gary M. Lampman; George S. Kriz; James R. Vyvyan Spectroscopy 2007. IR Spectroscopy, 26-92, Nuclear Magnetic Resonance Spectroscopy, 108-143, Mass Spectrometry, 401-477. Brooks/Cole.
- William Kemp (1991) Nuclear Magnetic Resonance Spectroscopy.Organic Spectroscopy 1991, 3, 101-193. ELBS, Macmillan.
- www.chemucla.edu/webspectra/notes on solvents.html
- OECD Guideline for Testing of Chemicals, Acute Oral Toxicity – Acute Toxic Class Method. Adopted: 17th December 2001,423.
- H. Gerhard Vogel Anti-inflammatory activity, Paw edema. Drug Discovery and Evaluation Pharmacological Assays 2002;2:759-761.Springer-Verlag Berlin Heidelberg, Germany.
How to cite this article:
Lavanya A, Parlapalli A, Ciddi M andSarangapani M: Novel 2 – Amino - N' - (2-Oxoindolin – 3 - Ylidene) Benzo [d] Oxazol – 5 -Carbohydrazides as Anti-Inflammatory Agents. Int J Pharm Sci Res2015; 6(1): 212-18.doi: 10.13040/IJPSR.0975-8232.6 (1).212-18.
All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.
Article Information
23
212-218
496KB
1701
English
IJPSR
A. Lavanya *, Arunadevi Parlapalli, Manasa Ciddi and Sarangapani M
University College of Pharmaceutical Sciences, Kakatiya University, Warangal, India
arunabpharm@gmail.com
25 May, 2014
24 July, 2014
20 September, 2014
http://dx.doi.org/10.13040/IJPSR.0975-8232.6(1).212-18
01 January, 2015